

REMARKS

Claims 1, 12-17, 19-36, 38-46, 48-53, and 75-78 are pending in the present application.

The rejection of Claims 1, 5, 6, 11-36, 38-46, and 48-90 under 35 U.S.C. §112, first paragraph (enablement), is obviated in part by amendment and traversed in part.

Applicants make no statement with respect to the propriety of this ground of rejection for the scope beyond β -glucans derived from a water extract of mushroom and in no way acquiesce to the same. Nonetheless, to expedite examination of this application and the claims embracing or relying upon β -glucans derived from a water extract of mushroom, Applicants have amended the claims to this scope that the Examiner indicates as having met the enablement requirement (see paragraph bridging pages 3-4 of Office Action mailed July 31, 2007).

Applicants request withdrawal of this ground of rejection.

The rejection of Claims 22 and 61 under 35 U.S.C. §112, second paragraph, is obviated by amendment.

Applicants have deleted the objected to parenthetical from Claim 22. Claim 61 has been canceled. As such this ground of rejection is believed to be moot.

Withdrawal of this ground of rejection is requested.

Applicants submit that the present application is in condition for allowance. Early notification to this effect is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Stephen G. Baxter, Ph.D.
Registration No. 32,884

Vincent K. Shier, Ph.D.
Registration No. 50,552

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 08/03)